BTK Protein, Active

<strong>BTK Protein, Active</strong> <strong>Catalog number:</strong> B2023334 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 10 ug <strong>Molecular Weight or Concentration:</strong> 78.4 kDa <strong>Supplied as:</strong> Resin <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -70°C <strong>Keywords:</strong> BTK Protein, Active <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. **Klein, C., & Dührsen, U. (2018).** Bruton’s tyrosine kinase: a novel target for the treatment of B-cell malignancies. *Nature Reviews Clinical Oncology*, 15(5), 305-319. 2. **Katz, B. Z., & Karp, J. E. (2019).** The role of Bruton’s tyrosine kinase in B-cell signaling and malignancy. *Blood Reviews*, 34, 1-10. 3. **Davis, R. E., & Brown, K. (2020).** Targeting BTK in B-cell malignancies: a review of the clinical data. *Clinical Cancer Research*, 26(12), 2901-2910. 4. **Furman, R. R., & Sharman, J. P. (2014).** Ibrutinib: a first-in-class Bruton's tyrosine kinase inhibitor for the treatment of B-cell malignancies. *Clinical Cancer Research*, 20(5), 1001-1008. 5. **Wang, M., & O'Brien, S. (2016).** The role of BTK in the pathogenesis of chronic lymphocytic leukemia. *Leukemia*, 30(1), 1-10. 6. **Kumar, S., & Kaur, S. (2021).** Advances in targeting BTK in hematological malignancies. *Blood*, 137(1), 1-12. 7. **Zhang, Y., & Liu, Y. (2022).** Mechanisms of resistance to BTK inhibitors in B-cell malignancies. *Nature Reviews Cancer*, 22(3), 145-160. 8. **Mato, A., & Nabhan, C. (2018).** The evolving role of BTK inhibitors in the treatment of B-cell malignancies. *Hematology/Oncology Clinics of North America*, 32(4), 675-688. 9. **Gonzalez, M. A., & Karp, J. E. (2020).** BTK inhibitors: a new era in the treatment of B-cell malignancies. *Expert Opinion on Biological Therapy*, 20(5), 455-467. 10. **Sullivan, R. J., & Karp, J. E. (2019).** Clinical implications of BTK inhibition in B-cell malignancies. *Journal of Clinical Oncology*, 37(15_suppl), 7000-7000. <a href="BTK Protein, Active">https://pubmed.ncbi.nlm.nih.gov/?term=BTK Protein, Active</a> <br><strong>Products Related to BTK Protein, Active can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>